Cargando…

Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival

Breast cancer is a heterogeneous disease with known expression-defined tumor subtypes. DNA copy number studies have suggested that tumors within gene expression subtypes share similar DNA Copy number aberrations (CNA) and that CNA can be used to further sub-divide expression classes. To gain further...

Descripción completa

Detalles Bibliográficos
Autores principales: Weigman, Victor J., Chao, Hann-Hsiang, Shabalin, Andrey A., He, Xiaping, Parker, Joel S., Nordgard, Silje H., Grushko, Tatyana, Huo, Dezheng, Nwachukwu, Chika, Nobel, Andrew, Kristensen, Vessela N., Børresen-Dale, Anne-Lise, Olopade, Olufunmilayo I., Perou, Charles M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387500/
https://www.ncbi.nlm.nih.gov/pubmed/22048815
http://dx.doi.org/10.1007/s10549-011-1846-y
_version_ 1782237099077926912
author Weigman, Victor J.
Chao, Hann-Hsiang
Shabalin, Andrey A.
He, Xiaping
Parker, Joel S.
Nordgard, Silje H.
Grushko, Tatyana
Huo, Dezheng
Nwachukwu, Chika
Nobel, Andrew
Kristensen, Vessela N.
Børresen-Dale, Anne-Lise
Olopade, Olufunmilayo I.
Perou, Charles M.
author_facet Weigman, Victor J.
Chao, Hann-Hsiang
Shabalin, Andrey A.
He, Xiaping
Parker, Joel S.
Nordgard, Silje H.
Grushko, Tatyana
Huo, Dezheng
Nwachukwu, Chika
Nobel, Andrew
Kristensen, Vessela N.
Børresen-Dale, Anne-Lise
Olopade, Olufunmilayo I.
Perou, Charles M.
author_sort Weigman, Victor J.
collection PubMed
description Breast cancer is a heterogeneous disease with known expression-defined tumor subtypes. DNA copy number studies have suggested that tumors within gene expression subtypes share similar DNA Copy number aberrations (CNA) and that CNA can be used to further sub-divide expression classes. To gain further insights into the etiologies of the intrinsic subtypes, we classified tumors according to gene expression subtype and next identified subtype-associated CNA using a novel method called SWITCHdna, using a training set of 180 tumors and a validation set of 359 tumors. Fisher’s exact tests, Chi-square approximations, and Wilcoxon rank-sum tests were performed to evaluate differences in CNA by subtype. To assess the functional significance of loss of a specific chromosomal region, individual genes were knocked down by shRNA and drug sensitivity, and DNA repair foci assays performed. Most tumor subtypes exhibited specific CNA. The Basal-like subtype was the most distinct with common losses of the regions containing RB1, BRCA1, INPP4B, and the greatest overall genomic instability. One Basal-like subtype-associated CNA was loss of 5q11–35, which contains at least three genes important for BRCA1-dependent DNA repair (RAD17, RAD50, and RAP80); these genes were predominantly lost as a pair, or all three simultaneously. Loss of two or three of these genes was associated with significantly increased genomic instability and poor patient survival. RNAi knockdown of RAD17, or RAD17/RAD50, in immortalized human mammary epithelial cell lines caused increased sensitivity to a PARP inhibitor and carboplatin, and inhibited BRCA1 foci formation in response to DNA damage. These data suggest a possible genetic cause for genomic instability in Basal-like breast cancers and a biological rationale for the use of DNA repair inhibitor related therapeutics in this breast cancer subtype. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-011-1846-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3387500
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-33875002012-07-12 Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival Weigman, Victor J. Chao, Hann-Hsiang Shabalin, Andrey A. He, Xiaping Parker, Joel S. Nordgard, Silje H. Grushko, Tatyana Huo, Dezheng Nwachukwu, Chika Nobel, Andrew Kristensen, Vessela N. Børresen-Dale, Anne-Lise Olopade, Olufunmilayo I. Perou, Charles M. Breast Cancer Res Treat Preclinical Study Breast cancer is a heterogeneous disease with known expression-defined tumor subtypes. DNA copy number studies have suggested that tumors within gene expression subtypes share similar DNA Copy number aberrations (CNA) and that CNA can be used to further sub-divide expression classes. To gain further insights into the etiologies of the intrinsic subtypes, we classified tumors according to gene expression subtype and next identified subtype-associated CNA using a novel method called SWITCHdna, using a training set of 180 tumors and a validation set of 359 tumors. Fisher’s exact tests, Chi-square approximations, and Wilcoxon rank-sum tests were performed to evaluate differences in CNA by subtype. To assess the functional significance of loss of a specific chromosomal region, individual genes were knocked down by shRNA and drug sensitivity, and DNA repair foci assays performed. Most tumor subtypes exhibited specific CNA. The Basal-like subtype was the most distinct with common losses of the regions containing RB1, BRCA1, INPP4B, and the greatest overall genomic instability. One Basal-like subtype-associated CNA was loss of 5q11–35, which contains at least three genes important for BRCA1-dependent DNA repair (RAD17, RAD50, and RAP80); these genes were predominantly lost as a pair, or all three simultaneously. Loss of two or three of these genes was associated with significantly increased genomic instability and poor patient survival. RNAi knockdown of RAD17, or RAD17/RAD50, in immortalized human mammary epithelial cell lines caused increased sensitivity to a PARP inhibitor and carboplatin, and inhibited BRCA1 foci formation in response to DNA damage. These data suggest a possible genetic cause for genomic instability in Basal-like breast cancers and a biological rationale for the use of DNA repair inhibitor related therapeutics in this breast cancer subtype. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-011-1846-y) contains supplementary material, which is available to authorized users. Springer US 2011-11-03 2012 /pmc/articles/PMC3387500/ /pubmed/22048815 http://dx.doi.org/10.1007/s10549-011-1846-y Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Preclinical Study
Weigman, Victor J.
Chao, Hann-Hsiang
Shabalin, Andrey A.
He, Xiaping
Parker, Joel S.
Nordgard, Silje H.
Grushko, Tatyana
Huo, Dezheng
Nwachukwu, Chika
Nobel, Andrew
Kristensen, Vessela N.
Børresen-Dale, Anne-Lise
Olopade, Olufunmilayo I.
Perou, Charles M.
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
title Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
title_full Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
title_fullStr Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
title_full_unstemmed Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
title_short Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
title_sort basal-like breast cancer dna copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387500/
https://www.ncbi.nlm.nih.gov/pubmed/22048815
http://dx.doi.org/10.1007/s10549-011-1846-y
work_keys_str_mv AT weigmanvictorj basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT chaohannhsiang basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT shabalinandreya basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT hexiaping basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT parkerjoels basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT nordgardsiljeh basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT grushkotatyana basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT huodezheng basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT nwachukwuchika basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT nobelandrew basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT kristensenvesselan basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT børresendaleannelise basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT olopadeolufunmilayoi basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival
AT peroucharlesm basallikebreastcancerdnacopynumberlossesidentifygenesinvolvedingenomicinstabilityresponsetotherapyandpatientsurvival